|October 09, 2012|
Functional Technologies Appoints Investment and Capital Markets Executive to Advisory Board
|Vancouver, BC --- October 9, 2012 --- Functional Technologies Corp. (TSXV:FEB; OTCQX:FEBTF) (the "Company") is pleased to announce the appointment of Dr. Lincoln Rathnam to its Advisory Board. Dr. Rathnam is an accomplished individual with a long and distinguished background in the investment industry globally.|
Dr. Rathnam's more than 30 years of founding, managing, strategic advisory and transactional experience includes senior positions (i.e. Managing Director) at Scudder, Stevens & Clark where he founded and managed the firm's high yield bond and private equity departments, rose to the position of chairman of the stock review committee, and also built Scudder's emerging markets fixed income assets under management to approximately US$1.7 billion by the end of 1995. Dr. Rathnam later held various management and/or senior advisory roles on investment roles, including as Managing Director of BCP Securities Asia Pte Ltd., President of Schooner Asset Management, partner at RHMK (USA), Inc. and Vistech Corporation, and continues today to advise private and early stage public companies in similar capacities. Prior to his career at Scudder, Stevens & Clark, he was an equity analyst at CIGNA Investment Management. Dr. Rathnam holds a PhD from Oxford University and a BA (Phi Beta Kappa) from Darmouth College. He is a Chartered Financial Analyst, a former director of the Boston Security Analysts Society, and is the author of numerous published articles on investing.
"I am both pleased and proud to be associated with the important advances that Functional Technologies has brought to consumer health and product quality," commented Dr. Rathnam.
Howard Louie, Chief Business Development Officer of Functional Technologies, stated "We are pleased that someone of Dr. Rathnam's extensive investment and business acumen has agreed to join us as an Advisor to the Company at this pivotal phase in the development of Functional Technologies, as we look forward to building on the momentum and interest cultivated for our lead technologies, our hydrogen sulphide-preventing and acrylamide-preventing yeast technologies for the wine and food sectors, respectively."
The Board of Directors
About Functional Technologies Corp.
Functional Technologies develops and commercializes proprietary, advanced yeast-based solutions to significant challenges in the food, beverage and healthcare industries. The Company's platform improves the performance of innate yeast functions, and prevents the formation of naturally occurring toxins and contaminants that either affect final product quality or are classified by the World Health Organization ("WHO") as probable human carcinogens. Functional Technologies' lead technologies include yeasts that prevent and reduce the formation of foul-smelling hydrogen sulphide (H2S) and the WHO classified probable carcinogen, acrylamide - both by-products of food and beverage processing. These contaminants are found in many commonly consumed items, such as fermented food products and alcoholic beverages, and baked and fried foods. For more information, please visit our website at www.functionaltechcorp.com.
For further information, contact:
VP, Business Development
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
To view release is PDF Format:
You can view the Next News Releases item: Wed Oct 10, 2012, Functional Technologies Closes Second Tranche of Private Placement
You can view the Previous News Releases item: Wed Oct 3, 2012, Functional Technologies Reports Increase in Non-Brokered Private Placement
You can return to the main News Releases page, or press the Back button on your browser.